(:ADMP)

Sep 07, 2023 12:00 pm ET
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small...
Aug 21, 2023 09:15 am ET
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023...
Aug 04, 2023 01:43 pm ET
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...
Aug 02, 2023 09:31 am ET
Thinking about buying stock in Tupperware Brands, Archer Aviation, Apellis Pharmaceuticals, Adamis Pharmaceuticals, or ABVC BioPharma?
NEW YORK, Aug. 2, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TUP, ACHR, APLS, ADMP, and ABVC.
Aug 02, 2023 08:30 am ET
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of...
Jul 28, 2023 08:30 am ET
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain...
Jun 26, 2023 09:31 am ET
Thinking about buying stock in MicroStrategy, Adamis Pharmaceuticals, Lulu's Fashion Lounge Holdings, Lucid Group, or Virgin Galactic?
NEW YORK, June 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSTR, ADMP, LVLU, LCID, and SPCE.
Jun 26, 2023 07:30 am ET
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol...
Jun 22, 2023 07:30 am ET
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with...
May 25, 2023 04:26 pm ET
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmaceuticals Corporation. The combined, publicly traded company will focus its efforts on...
May 19, 2023 12:00 pm ET
Adamis Pharmaceuticals Announces Reverse Stock Split
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m.,...
May 15, 2023 04:47 pm ET
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory...
May 08, 2023 04:05 pm ET
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and...
Mar 16, 2023 04:24 pm ET
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today...
Mar 14, 2023 04:01 pm ET
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and...
Mar 14, 2023 08:30 am ET
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and...
Mar 04, 2023 08:12 pm ET
Lifshitz Law PLLC Announces Investigations of RADI, ADMP, BTE, and ROCC
Radius Global Infrastructure, Inc. (NASDAQ: RADI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RADI to EQT Active Core Infrastructure and Public Sector Pension Investment...
Mar 03, 2023 07:21 pm ET
ADAMIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adamis Pharmaceuticals Corporation - ADMP
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Adamis Pharmaceuticals Corporation (the “Company”) (NasdaqCM: ADMP) with DMK Pharmaceuticals, Corp. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Mar 01, 2023 08:51 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, HRZN, ADMP, INFI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Ranger Oil Corporation (NASDAQ:...
Feb 28, 2023 09:00 am ET
ADMP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adamis Pharmaceuticals Corporation Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. is fair to Adamis shareholders.
Feb 27, 2023 04:05 pm ET
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, and...
Feb 22, 2023 04:01 pm ET
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and...
Nov 14, 2022 04:10 pm ET
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and...
Nov 07, 2022 04:05 pm ET
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor...
Oct 03, 2022 04:30 pm ET
Adamis Announces Review of Strategic Alternatives
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory...
Sep 21, 2022 07:30 am ET
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection did not achieve its...
Sep 12, 2022 04:05 pm ET
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248...
Aug 12, 2022 05:00 pm ET
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled. At the Annual Meeting, all items of business were considered, with the exception of...
Aug 10, 2022 04:02 pm ET
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and...
Aug 08, 2022 07:30 am ET
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor...
Jul 29, 2022 08:00 am ET
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended the Company’s stockholders vote FOR Proposal #2 and Proposal #3 on...
Jul 29, 2022 07:30 am ET
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19. The next Data Safety Monitoring Board...
Jul 21, 2022 07:30 am ET
Adamis Pharmaceuticals Issues Letter to Stockholders
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from...
Jun 01, 2022 08:00 am ET
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced that a meeting of the Data Safety...
May 26, 2022 04:05 pm ET
Adamis Appoints Vickie Reed to Board of Directors
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of directors. Richard Williams, Chairman of the Board, commented: “We are pleased to welcome Ms....
May 18, 2022 05:00 pm ET
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to...
May 16, 2022 04:35 pm ET
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the quarter...
May 09, 2022 05:56 pm ET
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor...
Mar 31, 2022 04:49 pm ET
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the year...
Mar 31, 2022 04:14 pm ET
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for...
Mar 24, 2022 07:30 am ET
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor...
Mar 22, 2022 07:30 am ET
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant...
Mar 21, 2022 04:05 pm ET
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The batches in the...
Mar 14, 2022 08:17 am ET
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate...
Mar 04, 2022 07:30 am ET
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. “Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided...
Feb 28, 2022 07:30 am ET
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COVID-19, an ad-hoc meeting of the Data...
Feb 18, 2022 04:05 pm ET
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory...
Feb 07, 2022 09:17 am ET
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now...
Jan 10, 2022 09:55 am ET
Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP.
Jan 10, 2022 07:30 am ET
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied...
Dec 01, 2021 07:30 am ET
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5...
Nov 23, 2021 02:39 pm ET
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from...
Nov 22, 2021 04:47 pm ET
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine...
Nov 19, 2021 03:34 pm ET
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor...
Oct 19, 2021 10:45 am ET
Thinking about buying stock in Progenity, Atea Pharmaceuticals, Peabody Energy, Adamis Pharmaceuticals, or Ion Geophysical?
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PROG, AVIR, BTU, ADMP, and IO.
Oct 18, 2021 08:30 am ET
Thinking about buying stock in Ion Geophysical, Valneva SE, Adamis Pharmaceuticals, Oyster Point Pharma, or InMed Pharmaceuticals?
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, VALN, ADMP, OYST, and INM.
Oct 18, 2021 07:30 am ET
Adamis Receives FDA Approval for ZIMHI
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a high-dose naloxone injection product...
Oct 04, 2021 07:30 am ET
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective...
Sep 02, 2021 07:30 am ET
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical...
Aug 24, 2021 04:05 pm ET
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr. Hopkins...
Aug 24, 2021 09:31 am ET
Thinking about buying stock in Bio-Path Holdings, AzurRx BioPharma, Adamis Pharmaceuticals, indie Semiconductor, or Orphazyme?
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BPTH, AZRX, ADMP, INDI, and ORPH.
Aug 24, 2021 07:30 am ET
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer reviewed journal, Clinical Immunology, entitled “Tempol, a novel antioxidant, inhibits both activated T cell and APC (Antigen Presenting Cell) derived...
Aug 19, 2021 09:31 am ET
Thinking about buying stock in MINISO Group, Adamis Pharmaceuticals, Sundial Growers, Palantir Technologies, or Zomedica?
NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNSO, ADMP, SNDL, PLTR, and ZOM.
Aug 19, 2021 07:30 am ET
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19 (TEMPOL: A Potential Home Treatment for COVID-19 | NIH COVID-19 Research). The NIH news stated that,...
Aug 04, 2021 04:05 pm ET
Adamis Announces Agreement to Sell Portion of US Compounding Business
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc. (USC), related to USC’s human compounding...
Jul 19, 2021 04:05 pm ET
Adamis Announces Results of 2021 Annual Meeting of Stockholders
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector of Election’s certified results from the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”), each of the Company’s nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Election’s report, stockholders approved all other proposals considered at the Annual Meeting, including the approval on an advisory ba
Jul 13, 2021 08:00 am ET
Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on July 16, 2021. In addition, the Board issued the following statement:
Jul 01, 2021 08:00 am ET
 Adamis Sends Letter to Stockholders to Address Jerald A. Hammann’s Costly, Distracting and Misguided Campaign
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders.
Jun 28, 2021 07:00 am ET
Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders.
Jun 14, 2021 09:00 am ET
Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent the below letter to stockholders. The letter has been signed by all five members of the Company’s Board of Directors: Howard C. Birndorf, Roshawn Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams.
Jun 11, 2021 07:30 am ET
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the Company’s experimental drug, in the treatment of COVID-19. Adamis is carrying...
Jun 09, 2021 07:30 am ET
Adamis Provides Update on ZIMHI™
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection...
Jun 07, 2021 07:30 am ET
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19. According to a study of cell cultures...
Jun 01, 2021 07:30 am ET
Adamis Pharmaceuticals Provides Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today provided the following business update. “The bulk of our...
May 28, 2021 04:04 pm ET
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25,...
May 26, 2021 03:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ:
May 26, 2021 11:30 am ET
The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ:
May 25, 2021 07:42 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NASDAQ: ADMP) investors concerning the Company’s possible violations of federal securities laws.
May 17, 2021 04:05 pm ET
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021, at 2 p.m. Pacific Time. The company filed a Form 12b-25 with the...
May 17, 2021 07:30 am ET
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was...
May 12, 2021 07:30 am ET
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on...
Apr 15, 2021 04:39 pm ET
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced financial results for the year ended December 31,...
Apr 13, 2021 04:03 pm ET
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on...
Apr 12, 2021 07:00 am ET
Adamis Pharmaceuticals Provides an Update on ZIMHI™
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI™ high-dose naloxone injection product intended for the treatment of opioid overdose. The...
Mar 15, 2021 09:00 am ET
Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes...
Feb 22, 2021 09:00 am ET
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that...
Feb 17, 2021 09:00 am ET
Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI™ high dose naloxone injection product candidate, intended for the treatment...
Feb 02, 2021 04:05 pm ET
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters'...
Jan 29, 2021 09:00 am ET
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,...
Jan 28, 2021 04:01 pm ET
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,...
Jan 28, 2021 09:00 am ET
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in collaboration with the Human Immune Monitoring Center at Stanford University have conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients....
Jan 26, 2021 09:00 am ET
Adamis Pharmaceuticals Provides Update On Its US Compounding Business
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of substantially all of the assets of its US Compounding Inc. (USC) subsidiary. Under the...
Jan 25, 2021 07:45 am ET
Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry
PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ -- Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer. An article in Nature.com recently said that: "The paramount achiev
Jan 21, 2021 04:05 pm ET
SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack,...
Jan 20, 2021 09:00 am ET
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to...
Dec 01, 2020 09:00 am ET
Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a planned response to a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its New Drug Application (NDA) for Adamis’ ZIMHI™ high dose...
Nov 16, 2020 06:45 am ET
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...
Nov 09, 2020 04:30 pm ET
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis...
Nov 05, 2020 09:00 am ET
Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of...
Sep 18, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,...
Sep 17, 2020 04:05 pm ET
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,...
Sep 03, 2020 04:05 pm ET
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was initially held August 20, 2020, and was adjourned until September 3, 2020.  At the reconvened meeting, the...
Aug 25, 2020 09:00 am ET
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided additional information concerning the proposals to be considered at its adjourned 2020 annual meeting of stockholders, which will resume on September 3, 2020 at 10:00 a.m. Pacific...
Aug 21, 2020 09:00 am ET
Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”), convened on Thursday, August 20, 2020, has been adjourned and will resume on September 3, 2020 at 10:00 a.m. Pacific...
Aug 17, 2020 04:40 pm ET
Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis...
Aug 14, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding...
Aug 05, 2020 04:05 pm ET
Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has received a letter from the NASDAQ Listing Qualifications Staff (“Nasdaq”) notifying the company that as a result of the closing bid price of the company’s common stock...
Jul 01, 2020 09:00 am ET
Adamis Pharmaceuticals Provides Update on SYMJEPI Products
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products...
Jun 18, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu...
Jun 15, 2020 10:30 am ET
Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?
NEW YORK, June 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, HTZ, BIOC, EDSA, and ADMP.
Jun 15, 2020 09:00 am ET
Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).  The license includes the worldwide use of Tempol...
May 27, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 ml of...
May 18, 2020 04:35 pm ET
Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals,...
May 18, 2020 09:00 am ET
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its ZIMHI™ (naloxone HCI Injection, USP) 5mg/0.5mL product...
May 15, 2020 09:00 am ET
Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, May 18, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the first quarter of 2020...
May 11, 2020 08:35 pm ET
Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) Injection 0.3mg, SYMJEPI® (epinephrine) Injection 0.15mg products currently marketed and available in the...
Apr 23, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys”...
Apr 21, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Production of Additional Drugs by its US Compounding Subsidiary to Aid in the COVID-19 Pandemic
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has increased its product mix to provide additional drugs to assist in the ongoing fight against COVID-19....
Apr 15, 2020 04:05 pm ET
Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Paycheck Protection Program (“PPP”).  The PPP, established as part of the Coronavirus Aid, Relief and Economic...
Apr 01, 2020 09:00 am ET
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has shifted part of its production to provide medical-grade hand sanitizers to hospitals and health care...
Mar 30, 2020 04:40 pm ET
Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated,...
Feb 21, 2020 09:15 am ET
Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $6.7 million of its common...
Feb 19, 2020 09:00 am ET
Adamis Pharmaceuticals Provides Update Regarding ZIMHI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission process. On November 22, 2019, Adamis received a Complete Response Letter (CRL) from the U.S. Food and Drug...
Dec 19, 2019 09:00 am ET
Adamis Pharmaceuticals Provides an Update on ZIMHI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission process. On November 22, 2019, the company received a Complete Response Letter (CRL) from the U.S. Food and...
Nov 25, 2019 08:00 am ET
Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of U.S. markets on November 22nd, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug...
Nov 18, 2019 09:00 am ET
Adamis Pharmaceuticals Announces Publication of Comparative Pharmacokinetics of Community Use Naloxone Formulations
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of Community Use Naloxone Formulations for Acute Treatment of Opioid Overdose” was accepted for publication...
Nov 12, 2019 04:28 pm ET
Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis...
Nov 06, 2019 04:05 pm ET
Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Tuesday, November 12, 2019 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of...
Nov 04, 2019 08:00 pm ET
Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received any notice of action from the U.S. Food and Drug Administration (“FDA”) on the company’s New Drug...
Oct 08, 2019 09:00 am ET
Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology (IHV) meeting...
Oct 01, 2019 09:00 am ET
Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ SYMJEPI® (epinephrine)...
Sep 26, 2019 09:00 am ET
Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that Dr. Ronald Moss, Chief Medical Officer, will be presenting data on October 4, 2019, pertaining to the company’s investigational high dose naloxone product candidate (ZIMHI) at...
Sep 03, 2019 09:00 am ET
Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHITM (naloxone) Injection, to a generic naloxone comparator. In June, the...
Aug 28, 2019 09:00 am ET
Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinephrine) 0.3 mg and 0.15 mg Injections. During this back-to-school season, there is a heightened awareness...
Aug 26, 2019 04:05 pm ET
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are very excited to bring on these...
Aug 14, 2019 09:00 am ET
Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No. 15/914,804) describing its...
Aug 08, 2019 04:30 pm ET
Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals,...
Aug 05, 2019 09:00 am ET
Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in the therapeutic areas of allergy, respiratory disease and opioid overdose, announced...
Aug 01, 2019 09:00 am ET
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today...
Jul 31, 2019 04:05 pm ET
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today...
Jul 24, 2019 09:00 am ET
Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the...
Jul 18, 2019 01:52 pm ET
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and kaléo Inc. agreed to settle all previously announced litigation between the parties, including the case filed by kaléo in the United States District Court...
Jul 09, 2019 08:30 am ET
Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric...
Jun 27, 2019 09:00 am ET
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaléo Inc. regarding kaléo’s claims of patent infringement relating to Adamis’ higher dose naloxone injection product (ZIMHITM), as well as, new...
Jun 11, 2019 09:00 am ET
Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the receipt of Adamis’ amendment to its previously submitted New Drug Application (NDA) for its higher dose naloxone...
May 29, 2019 09:00 am ET
Adamis Pharmaceuticals to Present at Conferences in June 2019
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019.  During the conferences, management from Adamis will discuss the company’s...
May 21, 2019 08:30 am ET
Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019, it received notice that it had been named and served as a defendant in a lawsuit filed by kaléo Inc. in the United States District Court for the District of...
May 14, 2019 09:00 am ET
Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proposed brand name for the company’s high dose naloxone product candidate. The notification to the...
May 09, 2019 04:30 pm ET
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals,...
May 07, 2019 09:00 am ET
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today...
Apr 18, 2019 07:55 am ET
Market Trends Toward New Normal in GrafTech International, Avinger, OraSure Technologies, Adamis Pharmaceuticals, Crinetics Pharmaceuticals, and Wayside Technology Group — Emerging Consolidated Expect
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd. (NYSE:EAF), Avinger, Inc. (NASDAQ:AVGR),...
Mar 15, 2019 04:39 pm ET
Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated,...
Mar 14, 2019 04:55 pm ET
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment of opioid overdose. On March 14, 2019, Adamis received FDA correspondence relating to the company’s NDA stating that the Agency had completed its filing review and had determined that the NDA was sufficiently complete to permit a substantive review. The FDA further provided a target agency action
Feb 26, 2019 06:54 pm ET
Adamis Provides Regulatory Update on Sublingual Tadalafil
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its sublingual tadalafil product....
Feb 20, 2019 09:00 am ET
Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that the article entitled “Higher doses of naloxone are needed in the synthetic opioid era” has been published in the peer reviewed journal Substance Abuse Treatment,...
Jan 16, 2019 04:18 pm ET
Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. (Sandoz), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency...
Jan 03, 2019 07:30 am ET
Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Driv
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Air Transport...
Dec 31, 2018 04:02 pm ET
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe (PFS) product candidate. This injection is...
Dec 28, 2018 07:46 pm ET
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its fast-dissolving sublingual tadalafil tablet.  This product candidate is designed...
Dec 06, 2018 09:30 am ET
Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz...
Nov 09, 2018 04:46 pm ET
Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated,...
Oct 09, 2018 07:50 am ET
Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global — Future Expectations, Projections Movin
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Cass Information...
Sep 27, 2018 04:05 pm ET
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I)...
Aug 27, 2018 12:02 pm ET
Adamis Pharmaceuticals Provides Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said, “We have been receiving a considerable amount of inquiries from...
Aug 10, 2018 09:00 am ET
Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated,...
Aug 06, 2018 04:05 pm ET
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the...
Aug 02, 2018 09:00 am ET
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the...
Aug 01, 2018 04:03 pm ET
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it...
Aug 01, 2018 08:30 am ET
Market Trends Toward New Normal in Horizon Global, Bio-Techne, Adamis Pharmaceuticals, Kadant, Semgroup, and Provident Financial Services — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon Global Corporation (NYSE:HZN), Bio-Techne Corp (NASDAQ:TECH),...
Jul 23, 2018 09:00 am ET
Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil.  Adamis intends to submit an investigational new drug...
Jul 01, 2018 08:00 pm ET
Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group, to commercialize Adamis’...
May 10, 2018 05:51 pm ET
Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said, “We...
Apr 19, 2018 08:25 am ET
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of J.Jill, Inc. (NYSE:JILL), BankUnited, Inc. (NYSE:BKU),...
Mar 15, 2018 05:59 pm ET
Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018.
Mar 08, 2018 09:00 am ET
Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immuno
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that a study titled “Human Factors Study in Untrained Adolescents Comparing Its Epinephrine Prefilled Syringe (Symjepi™) with EpiPen® Auto-Injector” was recently published in...
Mar 06, 2018 09:00 am ET
Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today provided an update on data from its presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment...
Feb 23, 2018 09:00 am ET
Adamis Pharmaceuticals Updates Symjepi Commercialization Plans
SAN DIEGO, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided an update on the progress of exploring commercialization options relating to the commercial launch of its SymjepiTM (epinephrine) Injection 0.3mg product, for the emergency...
Feb 12, 2018 09:00 am ET
Adamis Pharmaceuticals Announces FDA Acceptance for Review for the  Supplemental New Drug Application of Its Low Dose Symjepi Product Candidate
SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s supplemental New Drug Application (“sNDA”) for its...
Feb 09, 2018 07:55 am ET
Report: Exploring Fundamental Drivers Behind Vector Group, NovoCure, ORBCOMM, Adamis Pharmaceuticals, Calumet Specialty Products Partners, and Lakeland — New Horizons, Emerging Trends, and Upcoming De
NEW YORK, Feb. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vector Group Ltd. (NYSE:VGR), NovoCure Limited...
Dec 06, 2017 04:29 pm ET
US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses.  Ulcers are common in the majority of horses...
Dec 04, 2017 04:05 pm ET
Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin testing the drug compound...
Dec 01, 2017 09:00 am ET
Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephrine Pre-filled Syringe at the American Academy of Allergy, Asthma and Immuno
SAN DIEGO, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic...
Nov 29, 2017 04:05 pm ET
Adamis Pharmaceuticals Submits Prior Approval Supplement to FDA for the Pediatric Version of Symjepi
SAN DIEGO, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the submission of a prior approval supplement to the U.S. Food and Drug Administration (“FDA”) for a pediatric version (0.15mg) of Symjepi™.
Nov 21, 2017 07:30 am ET
Recent Analysis Shows Universal Display, Adamis Pharmaceuticals, Calumet Specialty Products Partners, Eldorado Resorts, PHH, and MRC Global Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Universal Display Corporation (NASDAQ:OLED), Adamis Pharmaceuticals...
Jun 15, 2017 02:31 pm ET
Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, June 15, 2017 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (“PFS”) for the emergency treatment of allergic reactions (Type I) including anaphylaxis.  The FDA has also approved the PFS trade name of Symjepi™....
Apr 26, 2017 04:05 pm ET
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, April 26, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the closing of its previously announced underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $3.50 per share, as well as 642,857 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters....
Apr 20, 2017 04:01 pm ET
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering.  The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any.  The proposed offeri...
Aug 03, 2016 09:00 am ET
Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No. 14/622,617). The approved claims describe the device and components that are important for its drug delivery functions. ...
Jul 29, 2016 08:45 am ET
Adamis Pharmaceuticals Announces $11.1 Million Registered Direct Offering
SAN DIEGO, July 29, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, and immunology, announced today that it has entered into definitive subscription agreements with investors pursuant to a registered direct offering for total gross proceeds of approximately $11.1 million. The closing of the transaction is expected to occur on August 2, 2016, subject to the satisfaction of customary closing conditions....
Jul 21, 2016 09:00 am ET
Adamis Pharmaceuticals Provides Update On License Agreement with Allergan plc 
SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has received notice from Allergan plc’s wholly owned subsidiary, Watson Laboratories, Inc. (“Watson”), that Watson has decided to terminate the previously announced license agreement to commercialize Adamis’ Epinephrine Pre-filled Syringe (“PFS”) product candidate for the emergency treatment of anaphylaxis in the United States.  This decision follows Adamis’ receipt from the FDA of a Complete Response Letter (“CRL”) in June and precedes the deadline ...
Jul 12, 2016 09:00 am ET
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, July 12, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,724,137 shares of Series A-2 Convertible Preferred Stock to a small number of institutional investors, and received gross cash proceeds of approximately $5,000,000.  The preferred stock is convertible into common stock at a conversion ratio of 1-to-1 at the option of the investor and has no preference to the common shares.  The Company also issued to the investor wa...
Jun 06, 2016 06:45 am ET
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO, June 06, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company”) announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product.  PFS is for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction.   A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review o...
May 10, 2016 06:45 am ET
Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
DUBLIN, Ireland and SAN DIEGO, May 10, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) has entered into an exclusive licensing agreement with Allergan plc’s wholly owned subsidiary, Watson Laboratories, Inc. (“Watson”), to commercialize Adamis’ Epinephrine Pre-filled Syringe (“PFS”) product candidate for the emergency treatment of anaphylaxis....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.